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Abstract  
These guidelines for Legally Defensible Workplace Drug Testing have been prepared and updated 
by the European Workplace Drug Testing Society (EWDTS).  
The European Guidelines are designed to establish best practice procedures whilst allowing 
individual countries to operate within the requirements of national customs and legislation. The 
EWDTS recommends that all European laboratories that undertake legally defensible workplace 
drug testing should use these guidelines as a template for accreditation. These guidelines are 
relevant to laboratory-based testing only.  These guidelines follow current best practices and are 
constantly under review. 
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General 
Introduction 
These guidelines represent an overview of the best practice for European laboratories providing oral 
fluid workplace drug testing services to maintain the legal defensibility of a drug test when the 
results, and the medical interpretation of the results are used in an employment disciplinary process,  
employment tribunal or a court of law. These guidelines are designed to ensure that the entire drug 
testing process is conducted to give accurate and reliable information about a donor's drug use.  
The updated oral fluid guidelines have been communicated within the members of EWDTS, experts 
from different countries - and accepted by the board.  
In the age of globalization the legal basis for workplace drug and alcohol testing has a complex 
structure consisting of international, European and national laws, acts and regulations from different 
levels (1). The European Workplace Drug Testing Society (EWDTS) has since 1988 offered a pan- 
European platform to allow all sectors involved in Workplace Drug Testing (WDT) to share best 
practices. 
Since 2010, first guidelines published with the aim to provide a “handbook” for specimen 
collection,  analysis of the specimen and interpretation of the results. Since that time there have 
been goals and specific directives which have impacted the WDT sector. This will continue with the 
impact of  further data protection and human rights legislation, for example, GDPR ( General Data 
Protection Regulations). The GDPR (EU- 2016/679) is a regulation by which the European 
Parliament, the Council of the European Union and the European Commission intend to strengthen 
and unify data protection for all individuals within the European Union (EU). In many European 
countries, there is no legal mandate to test, and conversely there is no legislation to prevent a test 
programme. 
Most countries have implemented a testing regime in safety critical workplace sectors, e.g. nuclear, 
transportation, refinery operations, and of course testing programmes within the military and prison 
systems are prevalent in many countries. 
Most of the European countries have no specific legislation on WDT. In Belgium, Greece, Slovenia, 
Sweden and Luxembourg further Acts like “Law on Safety and Health at the Workplace, Public 
Employment Act, Code for civil servants” and others permit pre-employment testing or 
occupational physicians are authorized to make examinations when required for specific jobs. 
In the Czech Republic, Estonia, Ireland, Lithuania, Slovakia WDT is regulated in the Labour Law 
or Safety, Health and Welfare at Work Acts or similar acts. In Italy since 2007 WDT is established 
and prescribed in the “Decree on Health and Safety at Work (81/08)” for jobs which bring out 
safety hazards to others (5). The Act on Workplace Drug Testing permits WDT in Finland. By 
contrast there is no legislation and only alcohol testing can be done in Hungary: “The Act on 
Labour Safety (No. 93/1993) does not authorize the labour safety controllers to make drug tests.”  
In Austria, the “Employee Protection Act” defines that the “employee is obliged not to be in a state 
caused by the use of alcohol, medicines and drugs that endanger themselves or others” - on one’s 
own authority. In Portugal, Germany the responsibility for workers’ safety and health is part of the 
employers’ duties.  
This “duty of care” requirement is common in many countries, and in turn. This mandate can be 
used to initiate a testing protocol. 
Regarding the hierarchy of jurisprudence and all the different national laws it is necessary to set up 
additional recommendations and to bring in line WDT procedures which were already common in 
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practice. Otherwise companies and institutions may not be able to implement the same procedure in 
all its offices, whether or not the headquarters are based in Europe. EWDTS attempts to ensure that 
WDT in Europe is performed to a defined quality standard and in a legally secured way. The three 
main points all EWDTS guidelines are collection of the specimen, analysing the specimen and 
interpretation of results. Some chapters handle with general aspects like “Laboratory Organisation”, 
“Quality Assurance and Quality Control” and these parts are identical in Urine and Oral fluid 
guidelines. 
In the Oral fluid guidelines  collection devices, collection procedures, chain of custody and validity 
testing are reported. As there are different kits on the market - the focus is on oral fluid collection 
devices, the components of the whole collection kit and the process of oral fluid collection. There 
should be a guarantee that all oral fluid collection devices fulfil the requirement for exact 
determination of known volume. There is the demand for precise determining of the oral fluid 
amount in the collected sample to ensure accurate calculation of drug concentrations. The use of 
“two sample containers, demonstrably clean and unused” as well a “tamper-evident seal for each 
container” are further requests. In the subchapter “Oral Fluid Collection Procedures” the demand 
for A and B samples is described. The measurement of endogenous biomarker in accordance with 
reference values, the accurate known dilution factor and sample volume are strongly recommended 
to verify the collected sample. Any uses of adulterants and efforts to tamper samples by the donors 
have to be uncovered forcefully. In summary the updated version of  the European Guidelines for 
Workplace Drug Testing in Oral fluid are geared to bring together different methods of operation 
and to ensure best practice procedures. 
Objectives 
• To provide a common framework for European providers of oral fluid workplace drug 
testing services. 
• To promote standards by providing guidelines which are accepted at a European level.   
• To ensure that the processes undertaken are capable of legal scrutiny. 
• To provide safeguards to protect the dignity of the specimen donors and the validity of 
the specimen. 
• To define for laboratories common quality assurance and quality control criteria that are 
capable of being accredited by an external body.  
• To ensure that the entire drug testing process is conducted to give accurate and reliable 
information about drug use of the donor. 
Scope 
These guidelines consider the three key stages of the workplace drug testing process. 
• Specimen collection: obtaining the oral fluid specimen from the donor  
• Laboratory analysis: analysis of the sample for the presence of drugs  
• Interpretation: review and interpretation of the analytical results  
Service Provision 
Where a service provider is contracted to deliver all the stages, they must ensure that the minimum 
criteria in this document are met in all the key areas.   
In those instances where a customer may undertake some stages of the process within their own 
organisation (e.g. specimen collection or interpretation), the service provider has a 'duty of care' to  
ensure that the customer understands the full implications of the drug testing process.  
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The service provider does not have the authority to make decisions regarding the fitness for work of 
any individual being tested. It is recommended that any issues related to fitness for work be referred 
to the company's medical representative.  
 
Drug testing in Context 
It should be explained to any purchaser of a laboratory drug testing service that drug testing should 
form part of an overall drug policy, which the purchaser has agreed with his employees and should 
have in place before testing is initiated.  
The service provider should have an effective company drugs policy in place. The policy may 
include drug testing of the staff involved in the analysis and reporting of workplace drug testing 
results. 
 
Outline of drug testing process 
Specimen collection 
Oral fluid specimens for legally defensible drug testing need to be collected under circumstances 
which respect the dignity of the individual whilst ensuring that the specimen is freshly collected 
Suitable records must be made when the specimen is collected to document that the specimen 
collected and the specimen received by the laboratory is one and the same.  
This is the first link in the chain of custody process which, when reconstructed at a later date, can be 
used to document that the final result belongs to the specimen collected.  
 
Analysis 
When the specimen is received at the laboratory, checks on the integrity of the specimen are carried 
out. Providing the specimen passes the integrity checks a portion of the specimen is taken and 
screened for the presence of drugs and sample validity. If the screen results are all negative no 
further analysis is necessary.   
However if the screen tests carried out indicate the possible presence of a drug (above a predefined 
cut-off level) a confirmation test to prove or disprove the presence of the drug or drug metabolite 
indicated by the screening test must be carried out on another portion of the specimen. 
When a negative result is obtained, either after the screen or confirmation test, it can be reported  
to the customer.  Positive results may require interpretation. 
 
Interpretation 
A laboratory positive result may be due to other reasons than intake of illicit drugs (i.e. prescribed, 
over-the-counter medication or dietary causes).  It requires interpretation that is best carried out by 
the laboratory toxicologist in conjunction with a qualified medical practitioner who can consult both 
with the donor and the donor’s medical practitioner.   
 
Record keeping 
Suitable records must be made during the analytical process to document that the specimen received 
by the laboratory and the specimen, about which the final report is written, are one and the same. 
All samples which prove positive for the presence of drugs, and all records of the analytical process, 
must be kept for an agreed period of time or according to national legislation to allow for any 
challenges to be made regarding the findings.   
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If the customer requires an independent toxicological review, the laboratory must make available, if 
requested, the analytical data upon which it based its final report. In table 1 the definitions adopted 
for these guidelines are reported. 
 
Oral Fluid Collection 
Introduction 
This is the first link in the chain of custody process which, when reconstructed at a later date, can be 
used to prove that the final result belongs to the specimen collected. 
The collection process must be carried out by someone formally assessed as competent and 
authorised to carry out the collection. Standard Operating Procedures (SOP) must be written for the 
collection process, the storage of collection devices, the training of Collecting Officers and the 
shipping of the collected specimen to the laboratory. These procedures must be followed precisely. 
Collection procedures must cover the following aspects: 
• Privacy and security of the specimen collection site 
• Steps to ensure that the specimen collection is  supervised 
• Steps to protect against tampering and adulteration 
• Identification of the donor giving the specimen 
• Evidence of the written informed consent of the individual to the analysis of the 
specimen (an example is given in Appendix B) 
• Disclosure of recent medication, or evidence that the individual was advised of the 
significance of recent medication 
• All information is considered as confidential. 
All specimens for legally defensible drug testing must be collected under circumstances that respect 
the dignity of the individual whilst ensuring that the specimen is freshly generated and has not been 
tampered with in any way. The collection site must be secure and the absence of potential 
interfering substances must be guaranteed. The validity of the specimen has to be guaranteed. 
Suitable records must be made when the specimen is collected to prove that the specimen collected 
and the specimen received by the laboratory is one and the same. 
Where the customer takes responsibility for the collection process, the service provider has a duty 
of care to ensure that these guidelines are understood. 
 
Personnel 
Specimens must be collected by suitably trained personnel (Collecting Officers). Although no 
healthcare professional education is required, documented training, which includes a demonstration 
of competence, must be undertaken before collections are performed. 
The training must include, at a minimum, instructions on the following: 
• The collection process 
• The storage and transport conditions of samples 
• The chain-of-custody process 
• Troubleshooting (i.e. how to deal with issues like refusal of the test, insufficient sample, 
suspicion of tampering of the sample, dry mouth) 
• The responsibility of the collecting officer for maintaining donor privacy, confidentiality of 
information, and specimen integrity. 
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• Ethical issues, especially regarding the declaration by the donor of the present use of 
prescribed medications. 
On successful completion of collector training a person may begin performing collections. 
 
Oral Fluid Collection Kits 
The laboratory and manufacturer must demonstrate that the device in no way impairs the ability of 
the laboratory to detect the drugs at the cut-off levels recommended in these guidelines. It is 
recommended that the device used to collect the oral fluid sample collects a known volume. This 
may be achieved through spectrophotometrically determination or through an integrated volume 
indicator. In case of uncertainty gravimetric analysis is strongly recommended. Scientific data 
which demonstrate the accuracy of the volume of any buffer (if used) and collected sample have to 
be available. The laboratory should be able to clearly identify which collection device has been used 
to collect the sample. 
The collection kit should comprise the following components: 
• Specimen collection device(s). 
• Chain of custody donor form.  
• A unique identifier that links the chain of custody form and sample containers. 
• At least two sample containers, demonstrably clean and unused. 
• Tamper-evident seal for each container. 
• Packaging components that satisfy current postal and courier regulations. 
 
Chain of Custody Forms 
The minimum information required on the Chain of Custody Form is: 
• Unique identification to link the form to the specimen container(s) (typically a barcode 
label or code number assigned to the sample). 
• Information uniquely identifying the donor. 
• Evidence that the donor identity has been confirmed. 
• Evidence that the donor has given informed consent for the specimen to be tested. 
• Date, time and place of collection. 
• Names and signatures of all individuals who had custody of the specimen during the 
collection process. 
• The opportunity to record any medication prescribed or non-prescribed that may have 
been taken in the days prior to the specimen being collected.  
• Copies for donor, employer and laboratory. 
 
Oral Fluid Collection Procedures  
One sample is collected and then split in the presence of the donor into two separate containers 
labelled sample A and sample B. 
It is acknowledged that currently some oral fluid collection devices cannot mechanically collect and 
generate two separate samples from the single collection procedure. In this case, two devices may 
be used to generate two samples. As these samples are discrete and not homogeneous the aliquots 
could be mixed and then divide into two aliquots (A and B).The sequential collection  should be 
done within 5 minutes away from each other. In addition the exact times of the generation of the 
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samples must be noted in the donor consent documentation. The two samples are then sent to the 
testing facility. Regardless of which type of device is used, there must be a “volume adequacy 
indicator” on the device to show to the collector that an adequate minimum volume has been 
collected, if two separate collection procedures are used to generate two samples. The receiving 
laboratory must gravimetrically or spectrophotometry determine a more precise quantity of 
collected oral fluid present in the container. When gravimetrical determination is used to measure 
collected oral fluid it is recommended to determine average net-weight of unused collection devices 
for each batch. This known amount of oral fluid is very important in the subsequent calculation of 
drug concentrations and individual manufacturer’s tolerances must be known and confirmed. In all 
cases the testing laboratory should receive two samples, labelled A and B. An example oral fluid 
collection protocol is detailed in Appendix A. 
 
Laboratory Organization 
A Quality Management System of the organization / laboratory is required via accreditation 
according to EN ISO/IEC 17025 and/or EN ISO 15189 in fields of forensic toxicology and/or 
workplace drug testing analysis.  
All personnel must have contracts with the institution (Laboratory Organisation) which they work 
for and every person must have agreed to the “confidentiality policy” of the institution (in written 
form).  
 
Personnel 
All personnel should adhere to the requirements of EN ISO/IEC 17025 and/or EN ISO 15189 
International Standards and as such, only staff who are suitably qualified and whose competence 
has been formally assessed can work within the laboratory. The laboratory must maintain accurate 
job descriptions for managerial, technical and key support personnel involved in the analytical tests. 
The laboratory must keep records that establish the individual’s qualifications / competency for all 
functions performed. The individual’s file must include an up-to-date curriculum vitae listing 
educational qualifications and previous employment experience, training and competency 
assessment records for the current tasks performed. Personnel performing specific tasks shall be 
qualified on the basis of appropriate education, training, experience and/or demonstrated skills, as 
required. All laboratory personnel must have received training in Health and Safety issues, the 
Control of Substances Hazardous to Health (COSHH) Regulations and other relevant legislation. 
The key functions outlined below are identified as the minimum requirement for a laboratory to 
maintain EN ISO 17025 and/or EN ISO 15189 accreditation for the provision of workplace drug 
testing services and/or forensic toxicology. It is acceptable for individuals to have responsibility to 
carry out more than one role. By virtue of the laboratory’s accreditation, it can be accepted that the 
appropriate qualifications for each role are in place. Role titles may vary between organisations, but 
the responsibilities will remain the same. 
 
Laboratory Security 
Drug testing laboratories must have a robust security system to ensure that no unauthorised 
personnel gain access to the laboratory processes or to areas where samples or records are stored as 
mentioned in EN ISO 17025 and/or EN ISO 15189.Unescorted access to these secured areas must 
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be limited to authorised individuals. The laboratory must maintain a record that documents the entry 
and exit of all visitors to the secured laboratory areas. The laboratory must maintain a record of all 
staff who are authorised to enter the secure laboratory areas. This list must be reviewed and updated 
on a regular basis. Sample containers must be retained within the secure laboratory area until the 
disposal date. 
 
Laboratory  Director 
There must be one person who has overall responsibility for the professional, organisational, 
educational, and administrative activities of the drug testing facility. 
This person is responsible for the day-to-day management of the drug testing laboratory. 
Some of the functions may be delegated to other appropriately qualified personnel but the overall 
responsibility for any delegated functions will remain with the designated Laboratory Director 
(typically the Laboratory Supervisor). 
 
Authorizing Scientist 
A person responsible for the review and certification of pertinent data and quality control results, 
prior to release of accurate and reliable analytical results. 
 
Laboratory Analyst 
A person responsible for undertaking the day-to-day analytical procedures. 
 
Toxicologist 
A person responsible for interpreting a toxicological analytical result for the customer or the 
customer’s designated Medical Review Officer. 
 
Expert Witness 
A person to present evidence to administrative or disciplinary proceedings that are based on 
analytical results reported by the laboratory. 
 
Quality Manager 
A person responsible for quality assurance within the laboratory organisation. 
 
Other Personnel 
Other technical or non-technical staff who must have the necessary training and skills for the tasks 
assigned. 
 
Laboratory Analysis Procedures 
Process 
When specimens are received at the laboratory, initial checks on the sample’s chain of custody and 
appearance are carried out. If the specimen passes these checks a portion of the specimen in 
container “A” is taken and goes through initial screening tests for the presence of drugs. Further 
testing of sample validity may also take place at this point. If the screening results are all negative 
(below a pre-defined cut-off level) no further analyses are necessary. However if the screening tests 
carried out indicate the possible presence of a drug (above a pre-defined cut-off level) a 
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confirmation test to prove or disprove the presence of the drug or drug metabolite indicated by the 
screening test must be carried out on another portion of the specimen.  
The screen-only presumptive positive test is not considered to be legally defensible, but may report 
preliminary presumptive positive results to the clients as local legislation allows. In the report it has 
to be mentioned that preliminary presumptive positive results need confirmation. If the first analysis 
is performed by a confirmation-level analysis (mass spectrometry), the positive findings have to be 
retested with another portion of the sample. 
 
Chain of Custody 
Laboratories must use chain of custody procedures to maintain control and accountability of 
specimens and aliquots from receipt through completion of testing, reporting of results, during 
storage, and continuing until final disposal of specimens and aliquots.  
Chain of custody records must be maintained on paper or in computerised form.   
 
Sample Receipt  
The laboratory should receive at least two sealed sample containers and a corresponding chain of 
custody form. At least one of these (referred to, in this document, as the “B” container) must be 
retained unopened and stored in conditions that reflect the storage of the sample under test (referred 
to, in this document, as the “A” container). 
When a sample is received in the laboratory: 
• Incoming orders and samples must be registered by the laboratory.  
• Incoming samples are immediately checked regarding completeness, intactness and 
suitability for testing. 
• Its packaging must be examined for evidence of tampering in transit. 
• The information on the sample containers within the package must be compared with 
the information on the accompanying chain of custody form. 
• Any discrepancies must be noted and, where appropriate, reported immediately to the 
customer. Some minor discrepancies may be tolerated in the documentation without 
termination of the analysis. These must be agreed with the customer prior to analysis 
and should be documented. 
• Appendix C lists examples of fatal flaws in the chain of custody and is provided for 
guidance. Flaws of this nature would normally result in the sample not being tested. 
 
Sample Processing 
Separate representative portions (aliquots) of the sample in container ‘A’ will be used for the 
screening and confirmation tests. The sample preparation should follow the standard operating 
procedure and the manufacturer’s instructions for the collection system being used. Aliquots must 
be taken in such a manner that excludes the possibility of contamination. 
Short-term storage: samples that are not currently undergoing analysis must be refrigerated at 2- 
8°C. Stability has to be investigated and appropriate measures undertaken to ensure the sample is 
valid for the analysis. The long term storage conditions are device dependent and the conditions 
should be as recommended by the device manufacturer. 
The A and the B samples must be stored under identical conditions. 
The quality control requirements must be satisfied when conducting either screening or 
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confirmation tests, either on single samples or samples grouped in batches. 
 
Oral Fluid Validity Testing  
The aim of validity testing is to demonstrate that the sample submitted for analysis is oral fluid. The 
validity of the sample must be checked either before or during the screening process. The minimum 
validity test that must be completed for oral fluid is the visual inspection of the sample(s), 
measurement of oral fluid volume and testing on matrix authenticity through measurement of 
endogenous biomarkers (e.g. salivary amylase, cortisol …). The laboratory may also test for 
adulterants and sample tampering. 
 
Following data have to be coherent: 
• Collection time  
• Dilution factor (gravimetrical analysis or measured spectro-photometry) 
• Sample volume 
• Endogenous biomarker in accordance with reference values (e.g. salivary Amylase, 
Cortisol…) 
 
Testing for Adulterants 
Additional validity tests should be considered when the following conditions are observed: 
• Abnormal physical characteristics (e.g., unusual colour or texture for the specific used 
device through bleeding, unusual odour, missing “pads”, … ) 
• Reactions or responses characteristic of an adulterant obtained during initial or 
confirmatory drug tests (e.g., non-recovery of internal standards, unusual response); or 
possible unidentified interfering substance or adulterant. 
 
A sample should be reported as e.g. “Sample cannot be used for screening and/or confirmation 
analysis” in the following situations: 
• A valid immunoassay drug test result cannot be obtained on two separate aliquots (e.g. a 
reasonable suspicion on interference occurred). 
• A valid drug test result cannot be obtained on two separate aliquots with drug 
confirmatory assay (a reasonable suspicion on interference occurred - e.g. components 
in the buffer which might interfere or cause ion suppression). 
• The physical appearance of the sample is such that testing the sample may damage the 
laboratory’s instruments.  
• Gravimetrical analysis exposes unexplainable deviation of weight (i.e. less weight 
caused by “sucked pads”; higher weight through water in the mouth.) 
• Spectrophotometrical analysis and measurement of endogenous biomarker indicates a 
dilution of the sample with water. 
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Analytical Methods and Validation 
Acceptable Screening Techniques 
Following methods are accepted e.g.: 
• Immunoassays 
• Gas Chromatography 
•  Liquid Chromatography as UPLC/UFLC 
• All chromatographic techniques coupled to mass spectrometry. 
• Capillary Zone Electrophoresis 
Laboratory Screening Tests 
The initial screening test must use an appropriate technique. The assay using the selected technique 
must be validated prior to its use. 
Recommended maximum screening calibration cut-off concentrations for workplace drug testing 
are listed in TABLE 2.  These recommended cut-off concentrations may be subject to change 
reflecting advances in technology and knowledge.  
Cut-off concentrations for substances not indicated in TABLE 2 will need to be agreed with the 
customer taking into account the performance of the assays to be used and the pharmacokinetics of 
the drugs involved. 
All screening test results must be reviewed with regard to the results of the validity tests performed. 
Samples that test negative on all the initial screening tests and pass the validity tests must be 
reported as negative and the samples can be disposed of as agreed with the customer. 
Samples that test negative on all the initial screening tests but fail the validity tests may be further 
investigated to determine the reason why. 
The presumptive presence for any drug following the initial preliminary screen must have the 
presence of the drug or drug metabolite confirmed (refer to section Confirmation Tests). If the first 
analysis is performed by a confirmation-level analysis (mass-spectrometry), the positive findings 
have to be confirmed and quantified by reanalysis with another portion of the sample. 
 
Standardization of Laboratory Screening Assays 
All assays must be calibrated against appropriate standards by following laboratory protocols based 
on the manufacturer’s recommendations or validated alternatives. The assay must be calibrated 
against one named compound, and the cross-reactivity to other related compounds must be 
determined. The customer must be informed of the limitations of the tests.  
 
Confirmation Tests 
The presence of the drugs indicated by a positive screening result must be confirmed using a 
chromatographic technique in combination with mass spectrometry (e.g. GC-MS or LC-MS). If the 
first analysis is performed by a confirmation-level analysis (mass spectrometry), the positive 
findings have to be confirmed and quantified by reanalysis with another portion of the sample. 
All confirmations must be quantitative. The customer must be informed of the compounds detected 
in the confirmation tests. Recommended maximum confirmation cut-off concentrations for 
workplace drug testing are given in TABLE 3.  The cut-off concentrations are a result of modern 
instrumentation techniques and the relatively short detection time window in oral fluid matrices. 
These cut-offs are the maximum recommended cut-offs for workplace drug testing purposes. 
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Confirmation cut-off concentrations may be subject to change as advances in technology or other 
considerations warrant identification of substances at other concentrations. 
Confirmation cut-off concentration for substances not indicated in Table3 must be agreed with the 
customer taking into account the performance of the assays to be used and the pharmacokinetics of 
the drugs involved. Samples that are below the agreed cut-off concentration must be reported 
negative. No further testing will be undertaken and the samples may be discarded as per the 
customer agreed timetable. 
Samples that contain drugs and/or metabolites at concentrations greater than or equal to the agreed 
cut-off level must be reported positive. 
Laboratories must adhere to national and international guidelines that specify additional criteria for 
chromatographic and mass spectral acceptability. 
 
Validation 
All methods must be validated and their suitability for intended purpose must be evaluated in 
accordance with EN ISO/IEC 17025. Laboratories accredited according to EN ISO 15189 should 
produce evidence of adequate method validation and certificate of participation to Proficiency Test 
and External Quality Assessment.  
The following parameters have to be determined at least for quantitative confirmation analyses and 
whenever possible, for screening analyses: precision, cut-off verification, selectivity, limit of 
detection, limit of quantification, sensitivity, specificity, stability, measurement uncertainty, 
recovery of the collection device and matrix effects. 
 
Authorization and Reporting of Results 
Before any laboratory test result is released, the results must be reviewed and certified as accurate 
by a competent member of staff (analytical validation). 
At a minimum, the report must include the specimen identification number and the test result 
(positive/negative) for each sample submitted. Reporting must be managed in accordance with EN 
ISO/IEC 17025 and/or EN ISO 15189 requirements. In addition the cut-off used for the test should 
be included. Only drugs that have been confirmed by a recognised confirmation test can be reported 
as positive. Samples that fail integrity or validity tests must be identified to the customer on the 
report. The laboratory must define and agree the meaning of all terms used in the report to the 
customer. Results must be transmitted to the customer’s designated representative in a manner that 
will ensure confidentiality of the information. Laboratory results should not be provided verbally. 
Written or electronic results must be transmitted to the customer’s designated representative in a manner that 
will ensure confidentiality of the information. 
 
Long-Term Storage of Samples 
The laboratory must demonstrate that the long term storage conditions of samples are adequate to 
ensure that analytes are stable over the time period required for any re-test. Currently long-term 
deep frozen storage (-20°C or below) indicates that most positive samples will remain suitable for 
any necessary retest. Unless otherwise authorised in writing by the customer, drug testing 
laboratories must retain all samples confirmed positive in properly secured long-term frozen storage 
for a minimum of 1 year. Within this one-year period the customer may request the laboratory to 
retain the sample for an additional period of time. If no such request is received, the laboratory may 
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discard the sample after the end of 1 year. The laboratory shall be required to maintain any samples 
known to be under legal challenge for a further agreed period. Samples must be retained within the 
secure laboratory area until the disposal date agreed with the customer. Negative samples (A+B) 
samples may be discarded as per the laboratory and customer agreed timetable. 
 
Records 
The laboratory must maintain and make available for an agreed period, documentation of all aspects 
of the testing process involved in the generation of a positive result. 
 
The required documentation must include: 
• Training and competency records for all individuals authorised to have access to 
samples and sample data. 
• Chain of custody forms 
• Quality assessment/quality control records 
• Standard operating procedures  
• All test data (including method validation, calibration curves and calculations for 
determining test results) 
• Maintenance and instrument calibration records 
• Reports 
• Records of proficiency testing and computer generated data 
 
The laboratory will be required to maintain documents for any sample under legal challenge for a 
further agreed period. 
Document control must be managed in accordance with EN ISO/IEC 17025 and/or EN ISO 15189 
requirements and records containing details of individuals should be dealt with in line with 
European Data Protection Legislation. 
 
Quality Assurance and Quality Control 
Quality Assurance 
Drug testing laboratories must have a quality management system which encompasses all aspects of 
the testing process including but not limited to: 
• Sample receipt 
• Chain of custody 
• Security and reporting of results 
• Screening and confirmation testing 
• Certification of calibrators and controls 
• Validation of analytical procedures 
Quality assurance procedures shall be designed, implemented and reviewed to monitor the conduct 
of each step of the testing process. 
The testing laboratory and all screening and confirmation tests used in workplace drug testing must 
be fully validated and accredited by a recognised external accreditation body.   
When an unaccredited method is used the customer should be informed accordingly. 
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Quality Control 
Calibrators and controls shall be prepared using either certified drug reference materials or certified 
standard solutions obtained from where possible two commercial manufacturers and should be 
appropriate to the matrix. If two manufacturers are not feasible then the controls should be taken 
from separate lots from the same manufacturer. 
The laboratory must retain records to demonstrate that all calibrators and controls are traceable back 
to primary standards (if available).  The calibrators and controls shall be properly labelled as to 
content, concentration, data placed in service and expiry date. All standards (e.g. pure reference 
materials, stock standard solutions, purchased standards) shall be labelled with the following: 
• Date received (if applicable) 
• Date prepared or opened or placed in service 
• Expiration date 
• Initials of the technicians who has prepared the (in house) calibrator etc. 
 
All data acquired on control samples as well lot number of drug reference materials must be 
recorded in such a way as to facilitate interpretation of control results and trends. 
 
Laboratory Screening Tests 
These are the minimum requirements for the suitable control of all laboratory screening tests. A 
system suitability check must be carried out prior to the analysis of samples. 
Screening tests are carried out using reagents and calibrators directly provided by the manufacturers 
provided the analysis is carried out according to the indications and the value of  cut-off defined by 
the manufacturer. Since the negative outcome of a screening analysis is generally accepted as valid, 
it is essential to verify that the method can minimize false negative results. 
Assays must be calibrated weekly or when quality control samples indicate poor performance. 
Control samples at concentrations of approximately 50% below and above the cut-off concentration 
for each drug group must be included in every batch of samples. These must be sourced 
independently from calibrators. Quality control samples must comprise at least 5% of the total 
number of samples in each batch being analysed. 
 
Confirmation tests 
These are the minimum requirements for identification of analytes and confirmation of results. 
Identification 
Mass spectrometry coupled to chromatography 
a) Mass spectrometry coupled to a chromatographic separation method is a very powerful 
combination for identification of an analyte in the sample extract. It simultaneously provides 
retention time, ion/charge ratios and relative abundance (intensity) data. 
 
Requirements for chromatography 
b) The minimum acceptable retention time for the analytes under examination should be at least 
twice the retention time corresponding to the void volume of the column. The retention time of the 
analytes in the extract should correspond to that of the calibration standard (may need to be matrix-
matched) with a tolerance of ± 1 %, for both gas chromatography and liquid chromatography.  
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Tolerance 1% means (with rt: retention time):  
 
𝑟𝑟𝑟𝑟𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑖𝑖𝑎𝑎 𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑎𝑎𝑎𝑎 − 𝑟𝑟𝑟𝑟𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑖𝑖𝑎𝑎 𝑐𝑐𝑎𝑎𝑎𝑎𝑖𝑖𝑐𝑐𝑐𝑐𝑎𝑎𝑎𝑎𝑐𝑐𝑐𝑐
𝑟𝑟𝑟𝑟𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑖𝑖𝑎𝑎 𝑐𝑐𝑎𝑎𝑎𝑎𝑖𝑖𝑐𝑐𝑐𝑐𝑎𝑎𝑎𝑎𝑐𝑐𝑐𝑐 ≤ 0.01 
 
Requirements for mass spectrometry (MS) 
c) Reference spectra for the analytes should be generated using the same instruments and techniques 
used for analysis of the samples. If major differences are evident between a published spectrum and 
the spectrum generated within the laboratory, the latter must be shown to be valid.  
 
d) Identification relies on proper selection of diagnostic (characteristic) ions. The (quasi) molecular 
ion is a diagnostic ion that should be included in the measurement and identification procedure 
whenever possible. In general, and especially in single-stage MS, high m/z ions are more specific 
than low m/z ions (e.g. m/z< 100).  
 
e) Extracted ion chromatograms of sample extracts should have peaks (exceeding S/N 3:1 of similar 
retention time, peak shape and response ratio to those obtained from a calibration standard analysed 
at comparable concentration in the same batch. Shift in retention time should not exceed 1% 
compared to calibration standard. Chromatographic peaks from different selective ions for the same 
analytes must overlap with each other. Where an ion chromatogram shows evidence of significant 
chromatographic interference, it must not be relied upon to quantify or identify residues. The ion 
that shows the best signal-to-noise ratio and no evidence of significant chromatographic 
interference should be used for quantification. 
 
f) In case of full scan measurement, careful subtraction of background spectra, either manual or 
automatic, by deconvolution or other algorithms, may be required to ensure that the resultant 
spectrum of the chromatographic peak is representative. Whenever background correction is used, 
this must be applied uniformly throughout the batch and should be clearly indicated. 
 
g) Different types and modes of mass spectrometric detectors provide different degrees of 
selectivity and specificity, which relates to the confidence in identification. General requirements 
for identification by MS-methods have been published and should be regarded as guidance criteria 
for identification, not as absolute criteria to prove presence or absence of a compound.  
 
h) The relative intensities or ratios of selective ions (full-scan MS or SIM) or product ions 
(MS/MS), expressed as a ratio relative to the most intense (product) ion, should correspond to those 
of the calibration standard at comparable concentrations and measured under the same conditions. 
Matrix-matched calibration solutions may need to be used. Table 4 indicates the maximum 
tolerances for ion ratios (6). 
 
i)The variability of ion ratios should preferably be determined from calibration standards during 
initial method validation and subsequently during routine analysis. Diagnostic ions should have an 
ion ratio of > 0.05 (least/most intense ion). 
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j) At higher deviation of the relative abundance of a qualifier ion, analysis needs to be repeated. If 
tolerances still remain beyond acceptance criteria, further investigation of influences of matrix 
effects or disturbing compound are recommended – such as standard addition experiments or 
chance of chromatographic system - to verify or to exclude the presence of a compound. In these 
cases complementary interpretation by an experienced analyst is recommended. 
 
k) For a higher degree of confidence in identification, further evidence may be achieved from 
additional mass spectrometric information. For example, evaluation of full scan spectra, isotope 
pattern, adduct ions, additional accurate mass fragment ions, additional product ions (in MS/MS), or 
accurate mass product ions. For High resolution (HRMS) the mass resolution shall typically be 
greater than 10000 for the entire mass range at 10% valley (which equates to resolving power of 
20000 FWHM (full width at half maximum). For accurate mass measurements (AMM) the 
instrument mass error in routine mass measurements must be less than 2 mDa and resolution shall 
typically be greater than 5000 FWHM. 
For combination of LC with HR-QToF-MS/MS or other mass spectrometric technique with          
HR-MS/MS the following settings are recommended for mass spectral identification based on a 
mass spectral library (commercial or home-made): 
For HR-QToF-MS/MS analysis a mass resolution of > 10000 amu with a mass accuracy of < 5 ppm 
and an isotope ratio comparability of better than 80% should be used in routine analysis. If 
comparison to a library is performed with MS/MS spectra, a fit value of > 70 % should be used as a 
threshold, for identification of compounds. Additionally, 1% tolerance of LC-retention time is 
required (see above, e).  
 
l) The chromatographic profile of the isomers of an analyte or any relevant metabolites may also 
provide evidence. Additional evidence may be sought using a different chromatographic separation 
system and/or a different MS-ionisation technique. 
 
Confirmation of results 
If the initial analysis does not provide unambiguous identification or does not meet the requirements 
for quantitative analysis, a confirmatory analysis of the A-sample is required. This may involve 
reanalysis of the extract or the sample. In cases where a detection threshold for a drug is exceeded, a 
confirmatory analysis of a portion of the B-sample may be required by the authorities. For unusual 
analyte/matrix combinations, a confirmatory analysis is also recommended. 
The use of different determination techniques and/or confirmation of qualitative and/or quantitative 
results by an independent expert laboratory will provide further supporting evidence. 
 
External Quality Assessment 
The laboratory must take part in appropriate external quality assessment schemes. When the scheme 
is not available, the laboratory has to conduct appropriate inter-laboratory testing to ensure 
appropriate assay performance. 
 
Sub-contracting 
Drug testing laboratories should carry out all laboratory work with their own personnel and 
equipment. If it is necessary to sub-contract, inter-laboratory transfer of samples is performed with 
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strict adherence to chain of custody procedures. The sub-contracted laboratory and its methods must 
be accredited by a recognised external accrediting body and compliant with these guidelines. 
Analyses undertaken by sub-contracted laboratories must be identified on the test report to the 
customer. 
 
Interpretation of Results  
A confirmed analytical positive result may be due to medication (prescribed or over-the-counter) or 
due to dietary causes. An essential part of the drug testing process is the final review of analytical 
results. The interpretation is best carried out by a qualified medical professional (e.g. Medical 
Review Officer) or a Forensic Toxicologist (depending on the country-specific situation). 
 
Toxicology Review 
It is mandatory that a toxicologist is available to advise the customer and/or Medical Review 
Officer regarding queries with test results. 
 
Medical Review  
The Medical Review Officer (MRO) is a medical physician with responsibility for interpreting 
laboratory results together with a toxicologist. Depending on the country-specific situation a 
medical physician usually has greater access to medical records than a toxicologist and may 
therefore be in a better position to provide interpretation of positive analytical results. 
The MRO must have specialist knowledge of and training in 
• specimen collection procedures, 
• analytical procedures, 
• chain of custody and 
• alternative explanations for positive analytical results. 
The MRO can issue a negative report for a positive analytical result if the test result is likely to be 
due to the use of declared medication, or a valid alternative medical explanation has been found. 
The service provider may provide access to an independent medical review service. 
 
Challenges to Drug Test Results 
In situations where there is a challenge to the results of a positive drug test result, the following 
guidelines must be used. The B sample should be released for analysis to a drug testing laboratory 
accredited by a recognised external accrediting body and working to these guidelines. This release 
requires authorisation from both the customer/MRO and the donor. 
The release must be supported by chain of custody procedures that can withstand legal scrutiny and 
include information about the findings of the original test (corresponding A sample) and the cut-offs 
used for the test. The original laboratory must retain the residue of the original sample and its 
containers so that it can be compared with the B sample at a later date if required. 
All laboratories that undertake B sample testing must be able to demonstrate that they can 
accurately determine the concentration of a drug or metabolite at 50% of the recommended 
confirmation cut-off concentration listed in Appendix E (or the cut-off used for the original test, 
whichever is the lower). On receipt in the testing laboratory, the B sample should follow chain of 
custody procedures as outlined. It is recommended that the laboratory should carry out validity 
checks outlined  prior to carrying out the confirmation analysis. Only those drugs identified for 
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confirmation testing should be looked for. The final report on the B sample must say either that 
there was no drug found, or a named drug was found at a level that is either consistent or 
inconsistent with the level in the corresponding A sample. Confirmation cut-off levels are not to be 
used as the determinant. There must be no comment on the final report that states whether the 
sample is positive or negative. 
 
Appendix A 
 
Oral Fluid Collection Procedure 
 (Note: Only formally competence tested and authorised persons may act as collecting officers. 
Medical qualification is NOT required for collecting officers.) 
I. Collection Site 
Procedures shall provide for a designated collection site to be secure. During the collection process 
the collection site must be dedicated solely to sample collection and comply with all local health 
and safety requirements. 
 
II. Access to Authorised Personnel Only 
Only authorised personnel shall be permitted in any part of the designated collection site when oral 
fluid samples are being collected or stored. 
 
III. Chain of Custody 
During the collection process chain of custody forms will be completed fully by the collecting 
officer and donor. 
 
IV. Identification of the donor 
When a donor arrives at the collection site, the collecting officer will request that the donor presents 
photographic identification. If the donor does not have acceptable photographic identification, the 
collecting officer will obtain a positive identification of the donor by an authorised supervisor or 
manager within the parent organisation. If the donor's identity cannot be established, the collecting 
officer will not proceed with the collection. 
 
V. Informing the donor about the test 
The donor has to be informed about the purpose and the content of the test. 
 
VI. Consent of the donor 
The donor gives his/her consent for oral fluid collection and analysis of drugs by signature. If the 
donor refuses to give a sample, - a note to this effect should be recorded on the form designated for 
that purpose. Appendix B gives an example of a Donor’s Statement of Informed Consent. 
 
VII. Privacy 
Procedures for collecting oral fluid specimens shall allow, where possible, for donor privacy during 
sample collection. Donors have to be treated equally regardless of gender and any physical 
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impairment. The process should avoid embarrassment but should also be rugged enough to satisfy 
challenge of the sample integrity. 
If there is a strong suspicion of sample adulteration and/or the previous sample was adulterated the 
sample can be collected under the supervision of collecting officer. 
 
VIII. Integrity of the Specimen 
The collecting officer must adopt procedures to minimise the risk of tampering and adulteration of 
the specimen during collection. The following minimum precautions shall be taken to ensure that 
unadulterated specimens are obtained and correctly identified: 
 
a) Throughout the collection process, the collecting officer will note any unusual behaviour of 
the donor on the chain of custody form. 
b) The collecting officer will ask the donor to remove any articles from the mouth e.g. chewing 
gum. 
c) The collecting officer will wait for 10 minutes to observe that the donor has nothing in their 
mouth. 
d) Oral fluid samples will then be collected from the donor and prepared for analysis in strict 
accordance with the standard operating procedure and the manufacturer’s instructions for 
the collection system being used.  
e) Upon receiving the specimen from the donor, the collecting officer will: 
• Note collection time 
• Check the volume of oral fluid on/in the specimen collection device. 
• Inspect the specimen to determine its colour and appearance of any signs of 
contaminants and adulteration. 
f) Any unusual findings will be noted on the chain of custody form. 
g) If the volume is less than that required by recommendation/order of the laboratory, the 
specimen will be discarded and a second specimen will be collected.  
h) If the donor is unable to provide a suitable volume of oral fluid for analysis then the 
collection process is stopped and advice should be sought. 
i) Both the donor and the collecting officer will keep the specimen container(s) in view at all 
times prior to the oral fluid specimen(s) being sealed and labelled. 
j) The collecting officer will request the donor to observe the transfer of the specimen to two 
sample containers and the attachment of the tamper-evident seal to the containers. The same 
is requested if split samples are obtained by two devices. The tamper-evident seal ensures 
that any tampering with the specimen will be evident to laboratory personnel during the 
laboratory receipt. 
k) The specimen container(s) will have an identification label that contains at a minimum; the 
date, the donor's specimen number and the donor’s signature/initials. The collecting officer 
will enter all information on the chain of custody form to identify the origin of the specimen. 
Both specimen containers and all pages of the chain of custody will be labelled at the time 
of collection with a unique identifier. 
l) The collecting officer will explain the significance relating to the drugs and medicines 
consumed within a minimum of 7 days prior to the provision of the oral fluid specimen. The 
donor will be given the opportunity to declare any medication used. 
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m) The donor will be asked to read and sign a statement on the chain of custody form certifying 
that the specimen identified on the form was in fact the specimen provided by the donor and 
giving informed consent for the work to be undertaken. Appendix B gives an example of a 
Donor’s Statement of Informed Consent. 
n) The collecting officer will complete the specimen chain of custody form and package with 
the oral fluid specimen ready for dispatch together to the analytical laboratory. If the 
specimen is not dispatched at once, the collecting officer during storage prior to dispatch 
must give appropriate consideration to the temperature and security of the specimens. It is 
advised that the specimens should be refrigerated whenever possible (do not freeze). 
o) Other pages of the chain of custody form will be given or forwarded to the appropriate 
persons. 
p) The collecting officer and the donor will be present throughout the procedures outlined in 
the paragraphs of this section. 
 
IX. Exceptional situations 
a. The donor wants to give the sample later 
The collecting officer must not allow the donor to leave the collection site and come back 
later to give a sample. The collecting officer will contact the appropriate authority to obtain 
guidance on the action to be taken. 
b. Admission of illegal drug use 
If the donor admits illegal drug use, this should be noted on the chain of custody form. 
 
X. Transportation to Laboratory 
Collecting officers will arrange to dispatch the collected specimens to the drug-testing laboratory. 
The specimens will be placed in containers designed to minimise the possibility of damage during 
shipment and packed properly to comply with local/international mail and courier regulations for 
biological specimens. Since specimens and the corresponding documents are sealed in packages 
that would indicate any tampering during transit to the laboratory by couriers, carriers, and postal 
services, usually there is no requirement for documented chain of custody procedures for the 
transport of the package. 
 
Appendix B  
 
Example of a Donor’s Statement of Informed Consent 
I confirm that I have received information about the meaning and content of the drug test. I confirm that I have provided 
a sample of my oral fluid to the specimen collector. I have observed the specimen being placed and sealed in the 
specimen containers and I confirm that the information on this form and on the specimen labels is correct. I hereby give 
permission for a minimum of two sealed specimen containers to be sent to the laboratory and I consent that they be 
tested for evidence of drug use and for tests to be carried out to confirm the validity of the sample. Furthermore, I 
understand that the results will be communicated confidentially to the employer or a designated representative. 
I consent to the above. 
Donor’s Name (Block Capitals):  _____________________________ 
Donor’s Signature:    _____________________________ 
Date:      _____________________________ 
Donor’s identifier on the specimen labels  
(if different from above):   _____________________________ 
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Appendix C 
Some Examples of Fatal Flaws in the Chain of Custody 
 
1. A unique identifier (e.g. barcode) mismatches or absent 
2. No documentation received with the sample 
3. No written consent to test from the donor 
4. Seals broken or tampered with on the sample container/transport container 
5. No seals  
6. Only 1 sample received  
7. Insufficient sample for complete analysis 
8. Leaking sample 
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